Cargando…

Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis

BACKGROUND: p16 protein is significantly down-regulated in several cancers, which reveals that it may be a potential biomarker for cancers. However, the clinicopathological and prognostic value of p16 protein in nasopharynx cancer patients remains unclear. Therefore, we performed a meta-analysis to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lingling, Song, Jingjing, Huang, Qingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426621/
https://www.ncbi.nlm.nih.gov/pubmed/30882625
http://dx.doi.org/10.1097/MD.0000000000014602
_version_ 1783405044059602944
author Sun, Lingling
Song, Jingjing
Huang, Qingli
author_facet Sun, Lingling
Song, Jingjing
Huang, Qingli
author_sort Sun, Lingling
collection PubMed
description BACKGROUND: p16 protein is significantly down-regulated in several cancers, which reveals that it may be a potential biomarker for cancers. However, the clinicopathological and prognostic value of p16 protein in nasopharynx cancer patients remains unclear. Therefore, we performed a meta-analysis to assess the relationships of p16 protein expression with the clinicopathological features and prognosis of nasopharynx cancer. METHODS: PubMed, Web of Science, Embase, and Chinese CNKI were searched to obtain eligible data. The relationships of p16 protein expression with risk, clinicopathological features, and prognosis of nasopharynx cancer were analyzed with stata 14.0 software. The pooled odds ratio (OR) with 95% CI (confidence interval) and hazards ratio (HR) with 95% CI were calculated to evaluate the association between p16 protein expression and nasopharynx cancer. RESULTS: A total of 28 studies with 2612 nasopharynx cancer patients were included in the meta-analysis. p16 protein expression was significantly associated with the risk, lymph node metastasis, TNM-stage (tumor-node-metastasis), distant metastasis, and T stage of nasopharynx cancer (Risk, OR = 17.82, 95% CI = 11.20–28.35; Lymph node metastasis, OR = 2.11, 95% CI = 1.42–3.14; TNM-stage, OR = 2.25, 95% CI = 1.54–3.28; Distant metastasis, OR = 3.43, 95% CI = 1.55–7.58; T-stage, OR = 1.72, 95% CI = 1.27–2.33). The negative rate of p16 protein expression in control group was 8.77%, while the negative rate of p16 protein expression in the nasopharynx cancer tissue was 63.78%. However, no significant associations of p16 expression with the overall survival and progression-free survival of nasopharynx cancer were found. CONCLUSION: The meta-analysis revealed that downregulated p16 expression was significantly associated with the risk, lymph node metastasis, TNM-stage, distant metastasis, and T stage of nasopharynx cancer. No significant association between p16 protein expression and prognosis of nasopharynx cancer was found. However, additional high-quality and multicenter studies should be conducted to validate these findings in the future.
format Online
Article
Text
id pubmed-6426621
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-64266212019-04-15 Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis Sun, Lingling Song, Jingjing Huang, Qingli Medicine (Baltimore) Research Article BACKGROUND: p16 protein is significantly down-regulated in several cancers, which reveals that it may be a potential biomarker for cancers. However, the clinicopathological and prognostic value of p16 protein in nasopharynx cancer patients remains unclear. Therefore, we performed a meta-analysis to assess the relationships of p16 protein expression with the clinicopathological features and prognosis of nasopharynx cancer. METHODS: PubMed, Web of Science, Embase, and Chinese CNKI were searched to obtain eligible data. The relationships of p16 protein expression with risk, clinicopathological features, and prognosis of nasopharynx cancer were analyzed with stata 14.0 software. The pooled odds ratio (OR) with 95% CI (confidence interval) and hazards ratio (HR) with 95% CI were calculated to evaluate the association between p16 protein expression and nasopharynx cancer. RESULTS: A total of 28 studies with 2612 nasopharynx cancer patients were included in the meta-analysis. p16 protein expression was significantly associated with the risk, lymph node metastasis, TNM-stage (tumor-node-metastasis), distant metastasis, and T stage of nasopharynx cancer (Risk, OR = 17.82, 95% CI = 11.20–28.35; Lymph node metastasis, OR = 2.11, 95% CI = 1.42–3.14; TNM-stage, OR = 2.25, 95% CI = 1.54–3.28; Distant metastasis, OR = 3.43, 95% CI = 1.55–7.58; T-stage, OR = 1.72, 95% CI = 1.27–2.33). The negative rate of p16 protein expression in control group was 8.77%, while the negative rate of p16 protein expression in the nasopharynx cancer tissue was 63.78%. However, no significant associations of p16 expression with the overall survival and progression-free survival of nasopharynx cancer were found. CONCLUSION: The meta-analysis revealed that downregulated p16 expression was significantly associated with the risk, lymph node metastasis, TNM-stage, distant metastasis, and T stage of nasopharynx cancer. No significant association between p16 protein expression and prognosis of nasopharynx cancer was found. However, additional high-quality and multicenter studies should be conducted to validate these findings in the future. Wolters Kluwer Health 2019-03-15 /pmc/articles/PMC6426621/ /pubmed/30882625 http://dx.doi.org/10.1097/MD.0000000000014602 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Sun, Lingling
Song, Jingjing
Huang, Qingli
Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis
title Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis
title_full Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis
title_fullStr Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis
title_full_unstemmed Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis
title_short Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: A PRISMA-compliant meta-analysis
title_sort clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: a prisma-compliant meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426621/
https://www.ncbi.nlm.nih.gov/pubmed/30882625
http://dx.doi.org/10.1097/MD.0000000000014602
work_keys_str_mv AT sunlingling clinicopathologicalandprognosticsignificanceofp16proteininnasopharynxcancerpatientsaprismacompliantmetaanalysis
AT songjingjing clinicopathologicalandprognosticsignificanceofp16proteininnasopharynxcancerpatientsaprismacompliantmetaanalysis
AT huangqingli clinicopathologicalandprognosticsignificanceofp16proteininnasopharynxcancerpatientsaprismacompliantmetaanalysis